Autolus Therapeutics (NASDAQ:AUTL)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report released on Monday, AnalystRatings.com reports. They presently have a $24.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 50.56% from the stock’s previous close.

A number of other equities analysts also recently weighed in on AUTL. William Blair reaffirmed a “buy” rating on shares of Autolus Therapeutics in a research report on Thursday, November 7th. Zacks Investment Research upgraded shares of Autolus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a report on Tuesday, November 12th. Finally, Needham & Company LLC began coverage on shares of Autolus Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $26.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and a consensus target price of $21.33.

Shares of Autolus Therapeutics stock traded up $1.20 during trading on Monday, reaching $15.94. The stock had a trading volume of 4,589 shares, compared to its average volume of 108,143. The company has a current ratio of 12.65, a quick ratio of 12.65 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $591.75 million, a price-to-earnings ratio of -11.23 and a beta of 0.85. The stock has a fifty day moving average price of $13.12 and a two-hundred day moving average price of $14.12. Autolus Therapeutics has a 52 week low of $9.50 and a 52 week high of $41.03.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.26. Autolus Therapeutics had a negative return on equity of 39.54% and a negative net margin of 3,576.93%. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $2.00 million. On average, equities analysts forecast that Autolus Therapeutics will post -2.66 EPS for the current fiscal year.

A number of large investors have recently modified their holdings of the business. Barclays PLC boosted its stake in shares of Autolus Therapeutics by 7,000.0% during the 3rd quarter. Barclays PLC now owns 3,195 shares of the company’s stock worth $40,000 after buying an additional 3,150 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in Autolus Therapeutics by 105.3% during the second quarter. Virtus ETF Advisers LLC now owns 17,311 shares of the company’s stock worth $279,000 after acquiring an additional 8,877 shares in the last quarter. CWM LLC raised its holdings in Autolus Therapeutics by 29.3% during the second quarter. CWM LLC now owns 45,384 shares of the company’s stock worth $731,000 after acquiring an additional 10,274 shares in the last quarter. Walleye Trading Advisors LLC acquired a new position in Autolus Therapeutics during the second quarter valued at approximately $168,000. Finally, Walleye Trading LLC acquired a new position in Autolus Therapeutics during the second quarter valued at approximately $170,000. 31.75% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Recommended Story: Insider Trading

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.